CREBBP and high grade B-cell lymphoma: Our analysis demonstrates that the presence of CREBBP mutations in tumor biopsies from patients with newly-diagnosed GCB DLBCL/HGBL is associated with poorer DFS following treatment with front-line immunochemotherapy.